Leading the way in DNA Methylation Diagnostic and Research Solutions
RiboMed provides a variety of versatile bisulfite-free research tools and services for the study of CpG methlyation in DNA.
RiboMed’s proprietary Abscription®-based diagnostic tests are leading the way in epigenetic cancer diagnostics.
RiboMed presents new brain cancer stratification test at Molecular Medicine Tri Conference.
RiboMed and NuvOx Pharma to Collaborate on Brain Cancer Drug and Companion Diagnostic Test
RiboMed and Austrian Institute of Technology Partner on Epigenetic Tests for Early Lung Cancer Detection, Sub-typing and Drug Response